<DOC>
	<DOCNO>NCT01147250</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate lixisenatide reduce cardiovascular ( CV ) morbidity mortality ( composite endpoint CV death , non-fatal myocardial infarction ( MI ) , non-fatal stroke , hospitalization unstable angina ) compare placebo type 2 diabetic participant recently experience acute coronary syndrome ( ACS ) event . Secondary Objectives : To demonstrate compare placebo , lixisenatide reduce : - composite endpoint CV death , non-fatal MI , non-fatal stroke , hospitalization unstable angina , hospitalization heart failure . - composite endpoint CV death , non-fatal MI , non-fatal stroke , hospitalization unstable angina , hospitalization heart failure , coronary revascularization procedure . - urinary albumin excretion ( base urinary albumin/creatinine ratio ) . To assess safety tolerability lixisenatide .</brief_summary>
	<brief_title>Evaluation Cardiovascular Outcomes Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 ( Lixisenatide )</brief_title>
	<detailed_description>The estimate maximum study duration first randomize participant approximately 204 week ( ± 14 day ) , median follow-up participant approximately 91 week , broken follow : - placebo-run-in period : 7 day ( + 3 day ) - double-blind study treatment period : 203 week ( ± 14 day ) ( 37 month recruitment period ) - post-treatment follow-up period : 3 day ( ± 1 day ) All participant follow randomization end study , occur last randomized participant follow approximately 10 month . The actual end date study `` event driven '' study end approximately 844 positively-adjudicated primary cardiovascular outcome event .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Inclusion criterion : Men woman experience spontaneous ACS event ( i.e. , STsegment elevation myocardial infarction ( STEMI ) nonSTsegment elevation MI ( NSTEMI ) unstable angina ) document elevation normal reference range cardiac biomarker ( Troponin Creatinine Kinase ( CK ) MB ) clinical presentation consistent ACS lead admission acute care facility , within 180 day follow ACS event prior screen . Participants history type 2 diabetes ( participant newly diagnose , diagnosis base World Health Organization ( WHO ) criterion : i.e. , either fast venous plasma glucose concentration ≥ 7.0 mmol/L [ 126 mg/dL ] 2hour post glucose load venous plasma glucose ≥ 11.1 mmol/L [ 200 mg/dL ] , confirm 2 occasion ) prior screen visit . Exclusion criterion : Type 1 diabetes mellitus history ketoacidosis within 6 month prior screen . Glycosylated hemoglobin ( HbA1c ) &lt; 5.5 % &gt; 11 % measure screening visit . Required use incretinbased agent ( e.g. , Glucagonlike peptide 1 ( GLP1 ) agonists Dipeptidyl Peptidase4 ( DPP4 ) inhibitor ) study drug doubleblind treatment period . Participants undergone coronary artery bypass graft ( CABG ) surgery follow qualify ACS event . Participants undergone percutaneous coronary intervention ( PCI ) within 15 day prior screen . Participants plan revascularization procedure ( PCI CABG ) coronary angiogram within 90 day screen visit . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease , personal family history medullary thyroid cancer ( MTC ) , genetic condition predisposes MTC ( e.g. , multiple endocrine neoplasia syndrome ) . Any clinically significant abnormality identify time screen judgment Investigator subInvestigator would preclude safe completion study constrain endpoint assessment major systemic disease . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>